AVICOVID-3 Inhaled Use of Zyesami for Treatment of Severe COVID-19
Conditions: SARS-CoV 2; COVID; ARDS; ALI; Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS); Dyspnea Interventions: Drug: ZYESAMI™ (aviptadil acetate); Drug: Placebo; Device: Nebulized administration of ZYESAMI™ or Placebo Sponsors: NeuroRx, Inc.; Cromos, LLC, Tbilisi, Georgia; Lugar Research Center, Tbilisi, Georgia Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials